Pfizer – Ends Immunostimulatory Conjugate Program
Pfizer has discontinued a Phase 1 immunostimulatory drug-conjugate program in oncology, highlighting challenges in developing next-generation targeted delivery modalities.
Pfizer
Pfizer – SF R&D Site Closure
Pfizer announced the closure of its South San Francisco research site, citing underutilization and broader pressures in the biotech funding environment. The move reflects ongoing post-pandemic restructuring across large pharmaceutical companies and signals shifts…
